Inscription Capital LLC Takes $3.86 Million Position in Johnson & Johnson (NYSE:JNJ)

Inscription Capital LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,418 shares of the company's stock, valued at approximately $3,863,000.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $29,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the fourth quarter worth approximately $36,000. Finally, Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $1.61 during mid-day trading on Wednesday, hitting $150.77. The stock had a trading volume of 8,323,506 shares, compared to its average volume of 7,959,915. The company has a 50 day moving average of $154.03 and a two-hundred day moving average of $153.69. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market cap of $362.76 billion, a PE ratio of 16.77, a PEG ratio of 2.35 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.45%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on JNJ shares. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.